The purpose of this study is to assess the safety and feasibility of HBOC-201 in increasing adequate wound healing in patients with severe peripheral vascular disease who are undergoing lower limb amputation. The hypothesis is that HBOC-201 will pass through the partially occluded lesions in the peripheral arteries in the lower extremity and promote the wound healing process by delivering oxygen to the oxygen deprived tissues. This will reduce the incidence of lower limb wound complications at 60 days post-surgery and may reduce the incidence of a second amputation.
This is a Phase II, single-blinded, prospectively randomized, parallel-group, placebo controlled study that will evaluate the safety and feasibility of HBOC-201 when administered therapeutically to patients with a peripheral vascular occlusive disorder and who are undergoing lower limb amputation due to critical lower limb ischemia. Subjects will be randomized (1:1) to receive either HBOC-201 or a colloid control (HAES-steril® 6%).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
16
intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
250ml for intravenous infusion
Johannesburg Hospital
Johannesburg, Guateng, South Africa
Milpark Hospital
Parktown West, Guateng, South Africa
Pretoria Academic Hospital
Pretoria, Guateng, South Africa
University of Stellenbosch
Tygerburg, South Africa
John Radcliffe Hospital
Headington, Oxfordshire, United Kingdom
Mortality at 60 days post amputation procedure
Time frame: 60(±7 days) post-procedure follow-up visit
30 day follow up mortality; Complete wound healing 30, 60 day follow up; Time to complete wound healing; Re-amputation 60 days; Hospital, ICU & rehab days; TcPO2 change; Quality of Life; Delayed wound healing/complications; Rehospitalization; Surgeries
Time frame: 15(±3 days) , 30(±7 days) and 60(±7 days) post-procedure follow-up visits
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.